Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Iran warns of potential change in nuclear doctrine if Israel targets facilities
    • UK executives dump shares on fears of Labour capital gains tax raid
    • Reeves weighs capital gains tax hike to help plug UK’s Budget gap
    • Florida surveys wreckage left by Hurricane Milton
    • French PM Michel Barnier unveils shock therapy in 2025 budget
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
    Most Read
    • UK executives dump shares on fears of Labour capital gains tax raid
    • Reeves weighs capital gains tax hike to help plug UK’s Budget gap
    • Ex-Darktrace head Poppy Gustafsson named UK investment minister
    • The battle of Labour’s three brains
    • Why are a rising number of young Britons out of work?
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Starboard plotted a campaign against Pfizer’s chief. Then a blank email dropped in his inbox
    • Private equity groups’ assets struggling under hefty debt loads, Moody’s says
    • Stellantis unveils management shake-up at global car brands
    • The ‘80-hour circuit breaker’: Wall Street banks tackle workloads of junior staff
    • Why Kamala Harris chose to appear on the ‘Call Her Daddy’ podcast
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • AMD rolls out new AI chip to rival Nvidia
    • Checking out of Hotel California
    • Why Big Tech makes such a poor babysitter
    • How Google plans to deflect and delay a historic break-up threat
    • US weighs Google break-up in landmark antitrust case
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • TD Bank to pay $3bn in US case over money laundering lapses
    • How Russia’s ‘shadow fleet’ gets its ships
    • Warren criticises accounting watchdog over BDO audit failures
    • China’s real intent behind its stimulus inflection
    • Former UBS chief Ralph Hamers joins AI wealth management start-up
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why Kamala Harris chose to appear on the ‘Call Her Daddy’ podcast
    • The battle of Labour’s three brains
    • The Ritz, London: Is this where I fall back in love with fine dining? — review 
    • How anime took over the world
    • China’s real intent behind its stimulus inflection
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • The ‘80-hour circuit breaker’: Wall Street banks tackle workloads of junior staff
    • Trump pledges to end double taxation for expat Americans
    • Herman Chinery-Hesse, tech entrepreneur, 1963-2024
    • Labour must keep listening to business
    • Would you trust a self-hypnosis app?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • The Ritz, London: Is this where I fall back in love with fine dining? — review 
    • How anime took over the world
    • South Korean author Han Kang wins Nobel literature prize
    • Introducing Ventete, the world’s first inflatable bike helmet
    • Peter Schlesinger: ‘It was drug-ridden back then — but a wonderful place’
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Disease control and prevention

  • Wednesday, 9 October, 2024
    Anjana Ahuja
    Marburg outbreak in Rwanda shows some post-pandemic progress

    It is too early to know whether the prompt response to the virus is enough to turn the tide

    Andy Carter illustration of two scientists working on a vaccine as a virus looms large over them
  • Monday, 7 October, 2024
    Europe Express
    EU court to hear case on von der Leyen’s texts with Pfizer next month Premium content

    Also in this newsletter: How greener corporate car fleets could boost competitiveness and the climate goals

    Ursula von der Leyen
  • Sunday, 6 October, 2024
    Drugs research
    Regeneron head says weight-loss drugs could cause ‘more harm than good’

    US biotech researches treatments to reduce muscle loss from blockbuster diet medicines

    Weight-loss injection pen parts at the Novo Nordisk A/S production facilities in Hillerod, Denmark
  • Wednesday, 2 October, 2024
    Science
    Map of adult insect’s brain offers clues on neurological diseases

    International collaboration plotted 149 metres of biological wiring in fruit fly

    Caption: The fruit fly connectome contains a wide range of information, from cell types and synapses to neurotransmitters and network properties. Here, cells are color-coded by their defining chemical messenger. Blue: GABA; yellow: acetylcholine (ACH); pink: glutamate (GLUT).
  • Wednesday, 2 October, 2024
    The Big Read
    Can Eli Lilly become the first $1tn drugmaker?

    The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’

    Montage image of David Ricks, chief executive of Eli Lilly, Zepbound medication and a building with the company’s logo on it
  • Wednesday, 2 October, 2024
    Artificial intelligence
    DeepMind and BioNTech build AI lab assistants for scientific research

    Artificial intelligence used to help researchers plan experiments and better predict outcomes

    Montage of Google DeepMind and BioNTech logos with a finger on a smartphone in the foreground and semiconductor chip design in the background
  • Tuesday, 1 October, 2024
    Eli Lilly & Co
    Eli Lilly considers testing weight-loss drugs on people who are not overweight

    Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’

    Zepbound  medication
  • Monday, 30 September, 2024
    Roche Holding AG
    Roche plans to launch drugs and slash development costs

    Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer

    A Roche Research laboratory
  • Friday, 27 September, 2024
    FT Magazine
    Inside the ‘killer cell’ factory

    The next stage in the war on cancer may be enlisting patients’ own blood cells to fight the disease

    Two men dressed in business suits standing side by side under a tree
  • Thursday, 26 September, 2024
    Anthony McDonnell
    Antimicrobial resistance is dangerous in more ways than one

    The reduced effectiveness of antibiotics risks severe disruption to the global economy

    Staff members work on the production line of penicillin antibiotics
  • Tuesday, 24 September, 2024
    The Big Read
    How tackling TB could help win the war on superbugs

    The lessons learnt from drug-resistant tuberculosis offer a path to beating back the ‘silent pandemic’ of antimicrobial resistance

    background: tuberculosis mycobacterium. foreground: Indian doctor with x-ray of patient diagnosed with TB
  • Monday, 23 September, 2024
    Pharmaceuticals sector
    GSK’s ex-vaccines chief says its jab for a flu-like virus is too expensive

    Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product

    Emmanuel Hanon
  • Sunday, 22 September, 2024
    Vaccine alliance battles for funds as donors face financial pressures

    Gavi chief Sania Nishtar offers rich nations long-term payment options for life-saving jabs

    A patient with mpox receives treatment in eastern Congo
  • Sunday, 22 September, 2024
    UK society
    Government urged to improve frontline health services after drop in childhood jabs

    Lack of appointments blamed for fall in take-up of key vaccinations

    A nurse is administering the NHS 4-in-1 pre-school booster and MMR second dose immunisation to a three-year-old girl who is sitting on a woman's lap.
  • Thursday, 19 September, 2024
    The Big Read
    Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’

    But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness

    Montage image of a bar chart, a person’s face and glowing lines representing neural pathways
  • Tuesday, 17 September, 2024
    Food security
    Malnutrition crisis threatens child health gains, warns Bill Gates

    Foundation says about 40mn children are at risk of stunted growth as climate change worsens food security

    A malnourished child looks on at the nutrition unit of the Gode General Hospital, in the city of Gode, Ethiopia
  • Tuesday, 17 September, 2024
    Drugs research
    AstraZeneca and MSD hail progress in tackling hard-to-treat cancers

    Results offer hope of progress in combating bladder tumours and some forms of breast cancer

    Doctor examines mammogram of breast
  • Sunday, 15 September, 2024
    News in-depthDrugs research
    Roche data shows stomach-churning side effects of weight-loss drugs

    High rates of vomiting among those who took strong doses in trials have unsettled investors

  • Saturday, 14 September, 2024
    Pharmaceuticals sector
    Pfizer warns Biden price controls could hurt cancer drugs development

    Company’s chief oncology officer says reforms risk discouraging treatments for paediatric and rare conditions

    Pfizer logo on an office in Belgium
  • Saturday, 14 September, 2024
    FT Magazine
    Storytelling with the pioneer of ‘narrative medicine’

    Rita Charon believes that letting patients tell their own stories is the best way to fix a broken system

    Rita Charon standing beside a wall filled with shelves of books and floor lamp
  • Friday, 13 September, 2024
    Philanthropy
    How do we know the money we give to charity will be well spent?

    Some opt for a data-led utilitarian approach; others say treat contributions like an investment portfolio

    An illustration of a hand adding a banknote to a charity ribbon of other banknotes
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Bird flu and mpox show little learnt from Covid about future pandemics

    More aggressive actions and better co-ordinated responses needed to contain viruses, say public health experts

    Several workers dressed in white protective coveralls are attending to rows of chickens inside a poultry farm
  • Thursday, 12 September, 2024
    Thomas Frieden
    We must strengthen public health surveillance to stop disease outbreaks

    Flying blind is dangerous. Technology can build on the basics of local and national data collection

    An individual wearing a white protective lab coat, gloves, and glasses is opening what seems to be a cryogenic tank
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Public health in global south faces vaccine cold storage challenge

    Issue hampers effort to exploit mRNA technology’s promise in tackling deadly viral outbreaks

    A female healthcare worker prepares a vaccine. Behind her in a chair is a woman and her baby
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Book review: surveying the four decades since Aids

    CDC officials recount the critical role of politicians and others surrounding the story of HIV

Previous page You are on page 1 Next page

Join us at an FT Live event

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Explore all events

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:UK
International
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • UK
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In